Compare Adaptive Biotechnologies Corp (ADPT) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs J B Hunt Transport Services Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.98 (market cap $4.04B), while J B Hunt Transport Services Inc trades at $274.24 (market cap $24.92B). The key difference: J B Hunt Transport Services Inc is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JBHT | |
|---|---|---|
Market Cap | $4.04B | $24.92B |
Sector | Health | Industrials |
52-Week High | $25.45 | $298.41 |
52-Week Low | $12.30 | $130.65 |
Enterprise Value | $4.10B | $26.06B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
JBHT stock trades at $266.14, down 0.89% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue trends show stabilization after a decline from 2022 peaks, while profitability metrics like ROE at 18.45% and net margin at 5.31% reflect efficient operations. Recent news highlights the company's 65th anniversary and partnerships to enhance freight technology.
The outlook is positive with a consensus price target of $299.82, implying 12.6% upside, supported by analyst buy ratings (57.78%). Risks include economic sensitivity impacting freight demand and competitive pressures. Earnings execution and intermodal demand recovery are key catalysts for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
